Skip to main content
CGON
NASDAQ Life Sciences

Phase 3 Win: Cretostimogene Cuts Bladder Cancer Recurrence Risk 68%

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$100.01
Mkt Cap
$6.645B
52W Low
$37.01
52W High
$80.97
52W Position info
170% above low
Off High info
at 52W high
Rel. Volume info
3.3× avg
Market data snapshot near publication time

CGON has more than doubled off its 52-week low of $37.01 on elevated volume (3.3× avg).

Summary

PIVOT-006 hit its primary endpoint: cretostimogene cut the risk of recurrence by 68% versus surveillance after complete tumor resection, with a hazard ratio of 0.32 (p<0.0001) and median follow-up of 17 months. Safety was clean — no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. That matters because roughly 50,000 intermediate-risk and high-grade Ta NMIBC patients have no FDA-approved adjuvant option today, so a positive registrational readout here opens a second commercial market on top of the BCG-unresponsive franchise. Management now plans a second BLA in intermediate-risk and high-grade Ta disease in Q2 2027, and, following FDA feedback, will broaden the initial BCG-unresponsive BLA to include high-grade papillary-only disease, pushing that submission to before the end of March 2027. The company has about $984.5M in cash and $500M still available under its ATM, so funding the filings is not the constraint — execution and FDA review are. Topline data get a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026.

At the time of this announcement, CGON was trading at $100.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $37.01 to $80.97. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CGON - Latest Insights

CGON
Nov 16, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $99.10
Real-time Price: $83.79 info
Change: -$15.31 (-15%) info
Market Cap: $7.454B info
CGON
Nov 06, 2026, 8:15 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $64.80
Real-time Price: $83.79 info
Change: +$18.99 (+29%) info
Market Cap: $7.454B info
CGON
Aug 07, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $75.10
Real-time Price: $83.79 info
Change: +$8.69 (+12%) info
Market Cap: $7.454B info
CGON
Aug 06, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $71.51
Real-time Price: $83.79 info
Change: +$12.28 (+17%) info
Market Cap: $7.454B info
CGON
Aug 06, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.51
Real-time Price: $83.79 info
Change: +$12.28 (+17%) info
Market Cap: $7.454B info